Strides Pharma Science Limited, a leading global pharmaceutical company, is consolidating its European business through Strides Pharma International AG, based in Zug, Switzerland. The move is expected to open up new opportunities and accelerate innovation within the European market.
Strides Pharma specializes in the development and manufacturing of IP-led niche finished dosage formulations, with over three decades of research and development expertise. The company is known for continuously delivering innovative products with improved technologies at competitive prices. Notably, Strides Pharma is one of the world’s largest manufacturers of Ibuprofen and Macrogol in various forms, making it a key player in the industry.
The newly appointed Chairman of the Board of Strides Pharma International AG, Oren Weininger, brings a wealth of experience to the role. Weininger has a longstanding leadership background, having previously held roles at Fairmed Healthcare, Dexcel Pharma, and Kamedis. He took on the role of CEO at Fairmed Healthcare AG in 2014 and became the owner in 2018. After a successful partnership, Strides Pharma invested in Fairmed Healthcare in 2019, further boosting the company’s product lines.
In addition to being appointed Chairman of the Board of Strides Pharma International AG, Weininger will continue to lead Fairmed Healthcare GmbH in Hamburg. His expertise and leadership will be crucial in driving the growth and success of Strides Pharma in the European market.
The consolidation of Strides Pharma’s European business through Strides Pharma International AG is expected to bring significant benefits to the company and its customers. The proximity to the European market in Zug, Switzerland, will enable rapid technology transfer and innovation, allowing Strides Pharma to respond faster to customer needs and provide flexible, innovative solutions.
Strides Pharma’s partner-centric in-licensing portfolio, which includes over 250 formulations, is consolidated in synergICE as a one-stop shop. This portfolio comprises generics, sterile injectables, value-added products, Women´s Health hormones, lyophilized orally dissolving tablets, and end-to-end biopharmaceutical CDMO services.
The key markets for Strides Pharma in Europe are Central and Southern Europe, especially Germany, Scandinavia, Benelux, and the Visegrád countries. With the strengthened European B2B presence, the company is well-positioned to expand its market reach and deliver its high-quality products to a wider audience.
For further information, please visit: www.fair-med.com/newsroom
Strides Pharma Science Limited, headquartered in Bangalore, India, has a global manufacturing footprint with eight facilities across four continents and a strong presence in 100 countries. The company is a key active pharmaceutical ingredient manufacturer and producer of various products, with every fourth Ibuprofen tablet on the global market being supplied by Strides Pharma.
Media Contact: Andreas Schöpf, What About Now Agency, as@whataboutnow.de, Tel. +49 160 90723690.
Derick is an experienced reporter having held multiple senior roles for large publishers across Europe. Specialist subjects include small business and financial emerging markets.